.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, individuals along with metastatic intestinal cysts that acquired biomarker-matched therapies based on spreading growth DNA profiling presented a greater clinical advantage than those getting unparalleled therapy.